The algorithm, developed using data from more than 7,00 chest pain patients, performed better than multiple techniques currently used to evaluate cardiac events. 

The primary concern is that sterilization facilities and healthcare providers would not have enough time to adapt to the proposal. Devices impacted would include pacemakers, angioplasty balloons and catheters, just to name a few. 

The new therapy, made from the pancreatic cells of deceased donors, is designed to help adult type 1 diabetes with severe hypoglycemia go a year or longer without needing to take insulin. 

A new meta-analysis, published in Frontiers in Cardiovascular Medicine, focused on data from nearly 3,000 patients with severe symptomatic aortic stenosis.

Dense calcifications have long been viewed as one of the most challenging aspects of TLE procedures. IVL may offer specialists a new way to address that issue. 

“Our pricing strategy for Lodoco is focused on helping to ensure access to as many people as possible,” an executive with Agepha Pharma told Cardiovascular Business. 

The FDA has said this is a Class I recall, which means using the devices “may cause serious injuries or death.” A total of 18 injuries have been reported so far. 

"The FDA's approval of colchicine confirms that we are entering a new era of patient care," said one veteran cardiologist familiar with the drug.